

**Nevada Medication Assistance Program (NV MAP)
For ALL Nevada AIDS Drug Assistance Program (ADAP) Members
Prior Authorization for Hepatitis C Treatment Regimens**

APPLICATION INFORMATION

Ramsell is the contracted PBM service provider for Nevada Medication Assistance Program (NV MAP). Requests for the prior authorization of Hepatitis C therapy will be reviewed for appropriateness of therapy by the Pharmacists in the Ramsell Clinical Services Department.

Please complete the attached supplemental form for Hepatitis C Treatment Regimens and fax to Ramsell at 800-848-4241. The request must include all of the supporting lab results and chart documentation for approval. For provider's questions regarding HCV treatment access, call Ramsell at 888-311-7632, Clinical Services Department.

FINANCIAL ELIGIBILITY

Patients must have current, non-temporary eligibility for a minimum of 8 weeks with the Nevada MAP program to be considered for coverage. They must maintain program coverage throughout the course of Hepatitis C treatment. If Nevada MAP has not confirmed eligibility at the time of the request, the application will be denied.

Approval Period: Authorization to receive Hepatitis C treatments are dependent upon the genotype, prior treatment regimens and/or a history of advanced liver disease (cirrhosis).

Limits: Treatment for Hepatitis C regimens are limited by program funding. Approval of this application is dependent on availability of Nevada ADAP funding.

Approval notification: Clinicians will be notified of the approval decision via fax along with the pharmacy noted on the form.

CLINICAL ELIGIBILITY

All supporting laboratory results and chart notes are **REQUIRED**:

- Baseline Complete Blood Count
- Hepatitis C Genotype
- Baseline Hepatitis C RNA viral load (within the last 3 months)
- CD4 count (within the last 6 months)
- HIV viral load (within the last 6 months)

If the patient has cirrhosis, please provide documentation to support the diagnosis of cirrhosis. Some examples include fibrosis staging, liver biopsy results and Child Pugh scoring:

- Fibrosis staging (METAVIR, FibroSure, etc)
- Liver biopsy results
- Child Pugh Score

Additional information: For the latest Hepatitis C treatment recommendations consult the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) Hepatitis C Treatment Guidelines at www.hcvguidelines.org.

